Curis to Present at Bio-Europe 2002 Conference
Friday November 8, 10:01 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2002--Curis, Inc. (NASDAQ-CRIS) announced today that Christopher U. Missling, PhD, Chief Financial Officer, will present at Bio-Europe 2002 8th Annual International Partnering Conference in Stuttgart, Germany, on Wednesday, November 13. Dr. Missling will provide corporate background and an update of Curis' therapeutic development programs, focusing on partnering initiatives in its proprietary signaling pathway technologies.
This conference is the premier European partnering conference where senior international decision makers in the biotechnology, pharmaceutical, and financial sectors meet to initiate and promote partnerships.
About Curis, Inc.
Curis, Inc. is generating therapies that regulate the pathways used by the body to maintain and restore health. The company focuses on signaling pathways that govern the proliferation and differentiation of cells. These same pathways control maintenance, repair, and regeneration of tissues and organs from infancy through old age. This approach has created an approved product for bone regeneration and enables Curis to build a portfolio of product candidates in neurology, kidney disease, and cancer. For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
--------------------------------------------------------------------------------
Contact:
Curis, Inc.
Henry W. McCusker, 617/503-6641
--------------------------------------------------------------------------------
Source: Curis, Inc. |
